Lilly’s gene-editing LDL story is part of a broader cardiovascular prevention push that is increasingly shaped by genetics-driven mechanisms and one-time dosing concepts. In parallel, early-stage and preclinical disclosures continue to suggest new ways to modulate disease pathways beyond statins and PCSK9 antibodies. The cluster of updates around PCSK9 gene editing reinforces how pharma is re-evaluating the tradeoffs between chronic biologic dosing and durable, potentially single-infusion approaches. While clinical endpoints remain early, Lilly’s ability to report sustained LDL lowering for up to 18 months adds credibility to a gene-editing pathway intended to change long-term treatment adherence dynamics. Market and clinical stakeholders will watch next steps—mid-stage trials and safety durability—as these programs could alter how lipid-lowering strategies are sequenced and reimbursed over time.